What does the
evidence tell us?
Registered for knee osteoarthritis in the EU since 2001.
A quarter-century in knee osteoarthritis (OA) care
DUROLANE registered for the treatment of knee OA in the EU.
DUROLANE uses advanced NASHA® technology designed to increase residence time in the joint.*1
CHASE study: a single DUROLANE injection noninferior to a 5-injection hyaluronic acid (HA) course.2
Post-market surveillance continues to confirm a low rate of adverse event reports.3
25 years on and the evidence is still growing.
DUROLANE 25 YEARS – The Checklist
Five reasons, twenty-five years of proof
-
-
Less pain walking – 93% of DUROLANE-treated patients had a decrease in pain over baseline while walking on a flat surface at week 18.2 -
26 weeks of pain control – 79% of patients experienced improved pain control versus baseline for 26 week.2
-
Physical function improved by 59% at 26 weeks (p<0.0001).2
-
Significantly improved quality of life as from early as 2 weeks, up to 24 weeks.4
-
Noninferior to corticosteroid at 12 weeks, with benefit still holding at 26 weeks while the steroid effect declined.†5
-
-
-
No serious safety signals were identified related to DUROLANE treatment in the pivotal trial.2
-
Treatment-related adverse events are generally local, mild and transient as reported in a systematic review of clinical studies on knee osteoarthritis (OA) pain. 6,7
-
Minimal immune response – non-animal, non-avian origin does not trigger significant antibody production.7
-
A history of safe use worldwide since 2001, with a low rate of post-market adverse event reports.3
-
Consistent safety profile with a low adverse event rate of 0.024% consistently over the past five years.3
-
-
-
Just one injection – no course of 3-5 weekly visits required.1,8
-
Convenience without compromise – all the convenience of a single injection, with lasting pain relief.1,3,8
-
Reduces reliance on oral pain medication – targeted relief that supports comfortable, everyday pain management.9
-
Ready to use – supplied as a ready-to-use 3 mL pre-filled glass syringe.8
-
Fits routine practice – well tolerated and easy to incorporate into standard workflows. 2,4,9
-
-
-
Highest molecular weight among 32 hyaluronic acids (HAs) – DUROLANE showed the highest molecular weight in a comparative study of 32 evaluated HA formulations.10
-
Longer reported half-life compared to other HA preparations.*11-14
-
~150-day joint residence based on a half-life of approximately 30 days.11
-
NASHA® technology – a carefully controlled minimal cross-linking process designed to produce an HA that resists degration in the joint. 1,15
-
Minimally modified – less than 1% modified, providing stabilization while remaining biocompatible.1
-
-
-
May delay TKR by years – patients receiving ≥5 courses of HA delayed total knee replacement (TKR) by 3.6 years.‡16
-
Fewer visits, lower cost – one injection vs 3-5 for many comparator HAs.
-
Efficient resource use – sustained symptom improvement that helps avoid extra interventions across the treatment journey.4
-
More clinic capacity – fewer appointments free up capacity to treat more patients.
-
Reduced injection-site risk – fewer injections mean less cumulative exposure to injection-related risk.
-
DUROLANE 25 YEARS – Live Webinar
Past, Present, and Future of OA Management: 25 Years of HA Therapy
Join Bioventus for a special webinar marking 25 years of DUROLANE, where leading orthopaedic surgeon Dr Neil Jain will explore the evolution of OA management and the changing role of HA therapy over the past quarter century.
Speaker:
Dr Neil Jain
Consultant Orthopaedic Surgeon
NHS Northern Care Alliance and Private Practitioner Northwest U.K
Honorary senior lecturer at the University of Salford
Current Vice President for the British Orthopaedic Sports Trauma & Arthroscopy Association (BOSTA)
Date:
November 25, 2026
Topics covered:
- The evolution of OA management and HA therapy over the last 25 years
- Key clinical evidence supporting HA and DUROLANE
- Positioning HA alongside steroids, PRP, biologics, and surgery
- Case study discussions and practical clinical insights
Register for the Webinar:
*Preclinical residence time has not been correlated with the duration of clinical effect. †In WOMAC subscores. ‡The Altman et al. 2015 study on HA and delay to TKR does not contain data specific to DUROLANE.
References: 1. Ågerup B, Berg P, Åkermark C. Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis. BioDrugs. 2005;19(1):23-30. doi:10.2165/00063030-200519010-00003 2. Zhang H, Zhang K, Zhang X, et al. Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis. Arthritis Res Ther. 2015;17(1):51. doi:10.1186/s13075-015-0557-x. 3. Bioventus LLC. Durolane Periodic Safety Update Report (PSUR) 2025. Data on file. RPT-100058. 2025. 4. Leighton R, Åkermark C, Therrien R, et al. NASHA hyaluronic acid vs. methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014;22(1):17-25. doi:10.1016/j.joca.2013.10.009. 5. Krocker D, Matziolis G, Tuischer J, et al. Reduction of arthrosis associated knee pain through a single intra-articular injection of synthetic hyaluronic acid. Z Rheumatol. 2006;65(4):327-31. doi:10.1007/s00393-006-0063-2. 6. Leighton R, Fitzpatrick J, Smith H, Crandall D, Flannery CR, Conrozier T. Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis. Open Access Rheumatol. 2018;10:43-54. doi:10.2147/OARRR.S162127. 7. Wooley PH, Song Z, Harrison A. Hyaluronic acid viscosupplements from avian and non-mammalian sources exhibit biocompatibility profiles with unique, source-specific, antigenic profiles. J Biomed Mater Res B Appl Biomater. 2012;100(3):808-16. doi:10.1002/jbm.b.32514. 8. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2022. 9. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis. 2013;2(1):1000108. doi:10.4172/2167- 7921.1000108. 10. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis. 2013;2(1):1000108. doi:10.4172/2167-7921.1000108. 11. Edsman K, Hjelm R, Lärkner H, et al. Intra-articular duration of Durolane™ after single injection into the rabbit knee. Cartilage.2011;2(4):384-8. doi:10.1177/1947603511400184. 12. Lindqvist U, Tolmachev V, Kairemo K, Åström G, Jonsson E, Lundqvist H. Elimination of stabilised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet. 2002;41(8):603-13. doi:10.2165/00003088-200241080-00004. 13. Larsen NE, Dursema HD, Pollak CT, Skrabut EM. Clearance kinetics of a hylan- based viscosupplement after intra-articular and intravenous administration in animal models. J Biomed Mater Res B Appl Biomater. 2012;100(2):457-62. doi:10.1002/jbm.b.31971 14. Sakamoto T.Biological fate of sodium hyaluronate (SPH) (1) Studies on distribution, metabolism and excretion of 14C-SPH in rabbits after intra-articular administration. Pharmacometrics. 1984;28(2):375-87. 15. Edsman K, Melin H, Näsström J. A study of the ability of Durolane™ to withstand degradation by free radicals while maintaining its viscoelastic properties. Poster presented at: 55th Annual meeting of the Orthopaedic Research Society; February 22-25, 2009; Las Vegas, NV. Poster 1149. 16. Altman R, Lim S, Steen RG, Dasa V. Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: evidence from a large U.S. health claims database. PLoS One. 2015;10(12):e0145776. doi:10.1371/journal.pone.0145776.
Summary Indications for Use:
DUROLANE is approved for the symptomatic treatment of mild to moderate knee osteoarthritis. DUROLANE has also been approved in Egypt, Hong Kong, India, Indonesia, Malaysia, and UAE for the symptomatic treatment of mild to moderate hip osteoarthritis. In addition, DUROLANE has been approved in Australia, New Zealand, Norway, EU, Switzerland, and the UK for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fi ngers, and toes, and for pain following joint arthroscopy in the presence of osteoarthritis within three months of the procedure.
Contraindications and Summary of Risks: DUROLANE should not be injected if the synovial joint is infected or severely infl amed. DUROLANE should not be injected if there is an active skin disease or infection present at or near the injection site. DUROLANE should not be injected intravascularly or extra-articularly or in the synovial tissues or capsule. DUROLANE should not be injected if the patient is known to be sensitive to hyaluronic acid-based products. DUROLANE should not be injected in patients with pre-existing chondrocalcinosis as injection may lead to an acute attack of the condition.
Risks can include transient pain or swelling of the infected joint.
The safety and effectiveness of the use of DUROLANE has not been established in pregnant women, nursing mothers, or pediatrics (21 years of age or younger).
Full prescribing information can be found in the product labeling, or at DUROLANE.com.
DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
NASHA is a registered trademark of Galderma Holding S.A.
©2026 Bioventus LLC. All rights reserved. SMK-100639A 09/26
